Argus Investors Counsel’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-27,940
| Closed | -$809K | – | 118 |
|
|
2024
Q3 | $809K | Sell |
27,940
-11,300
| -29% | -$330K | 0.53% | 68 |
|
|
2024
Q2 | $1.1M | Sell |
39,240
-8,200
| -17% | -$226K | 0.67% | 64 |
|
|
2024
Q1 | $1.32M | Buy |
47,440
+4,125
| +10% | +$114K | 0.81% | 57 |
|
|
2023
Q4 | $1.25M | Buy |
43,315
+6,350
| +17% | +$192K | 0.8% | 61 |
|
|
2023
Q3 | $1.23M | Buy |
36,965
+2,980
| +9% | +$105K | 0.88% | 55 |
|
|
2023
Q2 | $1.25M | Buy |
33,985
+1,620
| +5% | +$63.1K | 0.86% | 55 |
|
|
2023
Q1 | $1.32M | Buy |
32,365
+5,000
| +18% | +$216K | 1% | 49 |
|
|
2022
Q4 | $1.4M | Sell |
27,365
-525
| -2% | -$25.2K | 1.13% | 45 |
|
|
2022
Q3 | $1.22M | Sell |
27,890
-8,200
| -23% | -$398K | 1.09% | 41 |
|
|
2022
Q2 | $1.89M | Sell |
36,090
-400
| -1% | -$20.4K | 1.4% | 28 |
|
|
2022
Q1 | $1.89M | Sell |
36,490
-4,399
| -11% | -$228K | 1.21% | 41 |
|
|
2021
Q4 | $2.41M | Sell |
40,889
-14,050
| -26% | -$696K | 1.45% | 21 |
|
|
2021
Q3 | $2.36M | Sell |
54,939
-41,180
| -43% | -$1.82M | 1.55% | 21 |
|
|
2021
Q2 | $3.76M | Sell |
96,119
-7,110
| -7% | -$276K | 1.53% | 41 |
|
|
2021
Q1 | $3.74M | Buy |
103,229
+7,532
| +8% | +$267K | 1.51% | 44 |
|
|
2020
Q4 | $3.52M | Sell |
95,697
-27,600
| -22% | -$1.01M | 1.54% | 43 |
|
|
2020
Q3 | $4.29M | Buy |
123,297
+8,959
| +8% | +$314K | 1.78% | 29 |
|
|
2020
Q2 | $3.55M | Buy |
114,338
+5,797
| +5% | +$197K | 1.72% | 34 |
|
|
2020
Q1 | $3.36M | Buy |
108,541
+2,740
| +3% | +$93.4K | 2% | 27 |
|
|
2019
Q4 | $3.93M | Buy |
105,801
+4,003
| +4% | +$143K | 1.79% | 39 |
|
|
2019
Q3 | $3.47M | Hold |
101,798
| – | – | 1.68% | 42 |
|
|
2019
Q2 | $4.18M | Sell |
101,798
-1,128
| -1% | -$44.8K | 2.01% | 25 |
|
|
2019
Q1 | $4.15M | Sell |
102,926
-3,879
| -4% | -$155K | 1.98% | 25 |
|
|
2018
Q4 | $4.42M | Sell |
106,805
-9,349
| -8% | -$388K | 2.31% | 3 |
|
|
2018
Q3 | $4.86M | Sell |
116,154
-3,684
| -3% | -$142K | 2.09% | 14 |
|
|
2018
Q2 | $4.13M | Sell |
119,838
-989
| -0.8% | -$33.8K | 1.88% | 29 |
|
|
2018
Q1 | $4.09M | Buy |
120,827
+1,021
| +0.9% | +$35.1K | 2.03% | 21 |
|
|
2017
Q4 | $4.12M | Sell |
119,806
-1,021
| -0.8% | -$34.8K | 1.9% | 38 |
|
|
2017
Q3 | $4.09M | Sell |
120,827
-14,914
| -11% | -$479K | 2.03% | 21 |
|
|
2017
Q2 | $4.33M | Buy |
135,741
+7,780
| +6% | +$245K | 1.94% | 30 |
|
|
2017
Q1 | $4.15M | Sell |
127,961
-20,574
| -14% | -$649K | 1.94% | 29 |
|
|
2016
Q4 | $4.58M | Buy |
148,535
+4,453
| +3% | +$136K | 1.91% | 31 |
|
|
2016
Q3 | $4.63M | Sell |
144,082
-8,748
| -6% | -$293K | 1.95% | 26 |
|
|
2016
Q2 | $5.11M | Sell |
152,830
-3,584
| -2% | -$114K | 2.16% | 5 |
|
|
2016
Q1 | $4.4M | Sell |
156,414
-2,108
| -1% | -$60.2K | 1.83% | 40 |
|
|
2015
Q4 | $4.86M | Sell |
158,522
-3,689
| -2% | -$116K | 2.06% | 18 |
|
|
2015
Q3 | $4.83M | Sell |
162,211
-147
| -0.1% | -$4.71K | 2.11% | 14 |
|
|
2015
Q2 | $5.17M | Sell |
162,358
-11,046
| -6% | -$360K | 2.13% | 14 |
|
|
2015
Q1 | $5.72M | Buy |
173,404
+1,897
| +1% | +$60.3K | 2.3% | 4 |
|
|
2014
Q4 | $5.07M | Sell |
171,507
-8,432
| -5% | -$242K | 2.08% | 18 |
|
|
2014
Q3 | $5.05M | Buy |
179,939
+3,863
| +2% | +$108K | 2.11% | 17 |
|
|
2014
Q2 | $4.96M | Buy |
176,076
+9,415
| +6% | +$268K | 2.07% | 17 |
|
|
2014
Q1 | $5.08M | Sell |
166,661
-588
| -0.4% | -$17.5K | 2.09% | 14 |
|
|
2013
Q4 | $4.86M | Hold |
167,249
| – | – | 1.98% | 23 |
|
|
2013
Q3 | $4.56M | Sell |
167,249
-6,967
| -4% | -$190K | 2.06% | 22 |
|
|
2013
Q2 | $4.63M | Buy |
+174,216
| New | +$4.81M | 2.01% | 27 |
|
Other funds holding PFE
Argus Investors Counsel's PFE Position: Q4 2024 in Review
Argus Investors Counsel sold out of Pfizer (PFE) in Q4 2024, closing a stake of 27,940 shares — an estimated $809K sold.
Argus Investors Counsel first reported a position in PFE in Q2 2013 and held it in 46 quarters. The position peaked at $5.72M in Q1 2015. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- Argus Investors Counsel reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
- Argus Investors Counsel sold 27,940 Pfizer shares in Q4 2024, an estimated $809K.
- Argus Investors Counsel first reported a position in Pfizer in Q2 2013 and held it in 46 quarters.
- Argus Investors Counsel's Pfizer position peaked at $5.72M in Q1 2015.
- 2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on Argus Investors Counsel's 13F filing for Q4 2024, filed 27 Jan 2025.